"Our hypothesis is that impacting the CD40L pathway, a central mechanism in immune response, would translate to significant impact on SLE disease burden," said Diana Gallagher, who is leading ...

1 Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 2 Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine ...

Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

This is in part because lung cells can be driven to a profibrotic phenotype by multiple pathways that reinforce each other, so that targeting one pathway alone may not be effective to slow or stop ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

So, that's exciting news. The anifrolumab trial is moving along nicely. And so we might know soon, whether or not we might have an anti-interferon agent available for the treatment of lupus nephritis.

The Consultations on Resettlement and Complementary Pathways (CRCP), formerly the Annual Tripartite Consultations on Resettlement (ATCR) event is the most important multilateral forum for UNHCR, ...

Danites take Micah’s idols and his priest, Jonathan; Danites attack Laish; moral degradation; the Levite’s concubine slain. And it came to pass in those days, when there was no king in Israel, that ...

Rituximab led to the most profound decrease in the activity of the B cell pathway, while cyclophosphamide uniquely downregulated neutrophil activation pathways. Responders, regardless of medication, ...